Treatment Information

Back

Breast Cancer treatment details. Chemotherapy, Biologic therapy.

Institut Universitaire de Cancerologie Université Pierre et Marie Curie, Paris, France.

Survival: monthsCountry:France
Toxiciy Grade:5City/State/Province:Paris
Treatments:Chemotherapy, Biologic therapyHospital:Institut Universitaire de Cancerologie Université Pierre et Marie Curie
Drugs:Journal:Link
Date:Nov 2014

Description:

Patients:
This phase 3 study involved HER2-negative metastatic breast cancer patients who were divided into two separate treatment groups. There were 94 patients in group A with a median age of 54 years, and 91 patients in group B with a median age of 49 years.

Treatment:
Patients in group A received biologic therapy with bevacizumab and chemotherapy with docetaxel.

Patients in group B received biologic therapy with bevacizumab and chemotherapy with docetaxel and capecitabine.

Toxicities:
There was one treatment-related death due to heart failure in group A. Grade 3 gastrointeritis was also reported.

There was one treatment-related death due to kidney failure in group B. Grade 4 heart attack and grade 3 hand-foot skin reaction were also reported.

Results:
The median overall survival for groups A and B was 23.7 and 39.0 months, respectively.

Support:
This study was supported by F Hoffmann-La Roche.

Correspondence: Dr. Joseph Gligorov; email: joseph.gligorov@tnn.aphp.fr



Back